Melanoma is not one disease — it's dozens wearing the same name

Why this site exists

Melanomagroup.eu grew out of a simple frustration: clinical trial data from groups like EORTC is rigorous, but it's often locked behind dense abstracts and jargon that keeps patients, caregivers, and even curious clinicians at arm's length. I built this space to translate that research into language people can actually use — without dumbing it down or overpromising a cure that isn't there yet.

Here's what you'll typically walk away with:

• Plain-language summaries of new EORTC melanoma trial results
• Context on what a finding actually changes for patients today versus five years from now
• Explanations of staging, immunotherapy approaches, and follow-up protocols
• Honest notes on what remains uncertain or under debate in the field

A bit about me

I'm Eva Miller. My background is in analysis and science writing, not oncology practice, and I say that upfront on purpose — my job is to sit between the researchers and the reader, asking the questions a worried relative might ask at 2 a.m. after a diagnosis. Years ago, a family member's biopsy turned out benign, but the two weeks of waiting taught me how much clarity matters when fear is doing the thinking. That waiting room memory is still why I choose words carefully here.